Developing a rich pipeline of candidates with our most advanced product candidate entering IND-enabling development

The company’s team has a broad background in developing new drugs and moving through the regulatory process. The company has been granted FDA orphan drug designation for Hu-PHEC Liver to treat aplastic anemia, enabling a faster route to commercialization to get the therapies and treatments to patients most in need.

Preclinical and Clinical Development Stages

Our development milestones

Immunotherapy

Mechanism
Indication(s)
Product Name
Discovery & Development
Preclinical
Phase 1
Phase 2
Phase 3

Cell therapy

Mechanism
Indication(s)
Product Name
Discovery & Development
Preclinical
Phase 1
Phase 2
Phase 3